Regeneron Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Regeneron Pharmaceuticals Inc Unternehmen

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

Regeneron Pharmaceuticals Inc Informationen



BörsenkürzelREGN

Name des UnternehmensRegeneron Pharmaceuticals Inc

IPO-datumApr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

Anzahl der mitarbeiter15106

WertpapierartOrdinary Share

GeschäftsjahresendeApr 02

Addresse777 Old Saw Mill River Road

StadtTARRYTOWN

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl10591

Telefon17813705000

Websitehttps://www.regeneron.com/

BörsenkürzelREGN

IPO-datumApr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

Führungskräfte von Regeneron Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

54.39K

+1.82%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

54.39K

+1.82%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

Andere

421.70M

11.47%

Keine Daten

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

Andere

421.70M

11.47%

Aktionärsstatistik

Aktualisiert: Sat, Aug 30

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

9.07%

BlackRock Institutional Trust Company, N.A.

5.49%

State Street Investment Management (US)

4.68%

Dodge & Cox

3.70%

Fidelity Management & Research Company LLC

3.16%

Andere

73.90%

Aktionäre

Anteil

The Vanguard Group, Inc.

9.07%

BlackRock Institutional Trust Company, N.A.

5.49%

State Street Investment Management (US)

4.68%

Dodge & Cox

3.70%

Fidelity Management & Research Company LLC

3.16%

Andere

73.90%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

48.18%

Investment Advisor/Hedge Fund

28.87%

Hedge Fund

5.39%

Research Firm

2.72%

Pension Fund

2.56%

Bank and Trust

2.16%

Individual Investor

2.02%

Sovereign Wealth Fund

1.23%

Insurance Company

0.08%

Andere

6.77%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

2594

94.25M

91.26%

-4.09M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

9.37M

9%

+14.55K

+0.16%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.67M

5.44%

-75.61K

-1.32%

Jun 30, 2025

State Street Investment Management (US)

4.83M

4.64%

+42.34K

+0.88%

Jun 30, 2025

Dodge & Cox

3.83M

3.67%

+1.50M

+64.64%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.26M

3.13%

-4.14M

-55.90%

Jun 30, 2025

Capital International Investors

3.17M

3.04%

-823.87K

-20.65%

Jun 30, 2025

JP Morgan Asset Management

2.82M

2.7%

-1.26M

-30.95%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.47M

2.37%

-4.53K

-0.18%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

2.17M

2.09%

-7.70K

-0.35%

Aug 31, 2025

Putnam Investment Management, L.L.C.

2.03M

1.95%

+116.30K

+6.08%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: 6 hours ago

Name

Anteil

iShares Biotechnology ETF

5.44%

Amplify Weight Loss Drug & Treatment ETF

4.78%

JPMorgan Healthcare Leaders ETF

2.31%

SPDR S&P Biotech ETF

2.09%

Putnam Focused Large Cap Value ETF

1.57%

Pacer US Cash Cows 100 ETF

1.16%

Health Care Select Sector SPDR Fund

1.14%

JPMorgan Equity Premium Income ETF

0.8%

Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx

0.76%

Indexperts Quality Earnings Focused ETF

0.66%

iShares Biotechnology ETF

Anteil5.44%

Amplify Weight Loss Drug & Treatment ETF

Anteil4.78%

JPMorgan Healthcare Leaders ETF

Anteil2.31%

SPDR S&P Biotech ETF

Anteil2.09%

Putnam Focused Large Cap Value ETF

Anteil1.57%

Pacer US Cash Cows 100 ETF

Anteil1.16%

Health Care Select Sector SPDR Fund

Anteil1.14%

JPMorgan Equity Premium Income ETF

Anteil0.8%

Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx

Anteil0.76%

Indexperts Quality Earnings Focused ETF

Anteil0.66%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten